Preimplantation development in the mouse is characterized by the occurrence of several critical genetic and epigenetic events. Until recently, very little was known about the regulation of these events. The search for genes which are involved in the control of the earliest stages of mouse development has so far resulted in only a few candidates. Oct-4, a member of the POU transcription factor family, is encoded by a gene belonging to this group. Initially present as a maternal factor in the oocyte, Oct-4 is expressed by the embryo throughout the preimplantation period, as well as in germ cell precursors of adult mice. Oct-4 expression is correlated with an undifferentiated phenotype, both in the embryo and in cell lines derived from it. Regulation of the Oct-4 gene is dependent on the activity of two separate enhancers, one of which is specifically active in pluriand totipotent cells. Its function as a transcriptional regulator is supported by the identification of an increasing number of potential target genes, including some known to be essential for early embryonic development.
Introduction
During the short preimplantation period of mouse embryogenesis, progression from the fertilized egg to the implanting blastocyst is accompanied by a number of critical molecular and cellular events which must be carefully regulated ( Figure 1 ). The mechanisms which initiate and control these processes are currently central topics of investigation in developmental biology. Both classical genetic analysis and more recent gene targeting experiments demonstrate that many mutations which block development prior to implantation disrupt genes required for basic cellular functions. In general, these studies indicate that very few genes are essential for regulating preimplantation development (Magnuson, 1986; Copp, 1995) , although in some cases, the persistence of maternal factors may rescue what would otherwise be a lethal mutation (Murphy et al., 1997) , leading to a lower estimate of the number. Improved techniques for the detection and isolation of genes expressed in the early embryo have lead to the identification of several which could potentially be involved in the regulation of preimplantation events. These include growth factors and their receptors, as well as transcription factors and other nuclear proteins. In general, the evidence that these molecules may play a role in preimplantation rests mainly on their expression patterns and functional characteristics.
factors are thus responsible for regulation of the earliest events of embryo formation. This includes the transition from maternal to zygotic gene expression, which occurs at the 2-cell stage in the mouse (Schultz, 1993; Nothias et al., 1995) . The onset of zygotic gene activation (ZGA) is regulated in a timedependent manner, the mechanism of which is not yet clear (Nothias et al., 1995) . It is known to involve the delayed activation or expression of maternal factors required for both transcription and translation (Schultz, 1993; Nothias et al., 1996; Wang and Latham, 1997) , and to be dependent on protein kinase activity (Schultz, 1993) .
ZGA is accompanied by chromatin-mediated repression of the genome at the 2-cell stage (Nothias et al., 1995) . The repression is correlated with changes in the synthesis and modification of histones, and extensive chromatin remodeling observed in early embryos (Thompson et al., 1995; Worrad et al., 1995; Wiekowski et al., 1997) . The mRNAs for all five major histones are present in fertilized oocytes, but the synthesis of histones H2A, H2B and H1 is delayed until the 2-cell stage (Wiekowski et al., 1997) . In addition, changes in histone H4 modifications and spatial localization occur slightly later, between the 2-and 4-cell stages (Thompson et al., 1995; Worrad et al., 1995; Weikowski et al., 1997) . Regulation of histone composition in the 2-4-cell embryo is thought to be related to the general repression of chromatin and transcription which accompanies ZGA.
At the 2-cell stage, enhancer function becomes a requirement for gene expression, particularly for transcription of weak promoters (Majumder et al., 1993) . Enhancer activity is developmentally acquired at this time, due to the induction of either an enhancer-specific cofactor (Majumder et al., 1997) , Figure 1 . Oct-4 expression in the early mouse embryo. The progressive stages of murine preimplantation development, through implantation and gastrulation (embryonic days 0.5-6.5), are schematically represented. Critical genetic and epigenetic events initiated during this period are indicated at the appropriate time points. The expression pattern of Oct-4 mRNA and protein in the developing embryos is represented by shading, with the intensity of colour reflecting the level of expression. Oct-4 is present in the nuclei of all cells through the morula stage. At day 3.5, Oct-4 becomes restricted to the inner cell mass (ICM), and later, at day 4.5, to migrating cells of differentiating primitive endoderm. Following implantation, Oct-4 expression is limited to primitive ectodermal cells. Expression in primordial cells is detectable at day 8.5 (not shown).
or of stage-specific transcription factors (Wang and Latham, 1997) , or both.
Significant demethylation of the embryonic genome occurs during cleavage, leaving the embryonic DNA predominantly unmethylated (Jaenisch, 1997) . Sometime between implantation and gastrulation, this process is reversed and inherited methylation patterns are re-established. Maintenance of the allele-specific imprints relies on 'imprinting boxes' which, in contrast to the rest of the genome, retain their methylation pattern (Jaenisch, 1997) . This suggests that, prior to gastrulation, the methylation status of most genes does not affect their regulation, although the expression of a subset of imprinted genes is regulated during this time (Latham et al., 1995; Trembley et al., 1995) . Another epigenetic modification initiated in the preimplantation embryo is the inactivation of an X chromosome in the somatic cells of female mammals. During early cleavage stages, both X chromosomes are active. X inactivation begins at the blastocyst stage in cells of the trophectoderm and primitive endoderm, with the non-random silencing of the paternal X chromosome (Takagi and Sasaki, 1975) . Subsequent random inactivation of one X chromosome occurs in somatic cells of the embryo over a period of time, beginning at 5.5 days after fertilization (Tan et al., 1993) .
Evidence for an influence of maternal determinants on embryonic patterning has recently challenged previous theories of mammalian development. The organization of the mouse oocyte and zygote is now recognized to have an influential role in the subsequent development of the embryo (Gardner, 1996; Edwards and Beard, 1997) . Specification of blastocyst bilateral symmetry and subsequently, of patterning in the embryo has been found to be linked to that of the zygote (Gardner, 1997) . In fact, at least two maternally derived proteins, leptin and STAT3 are polarized in mouse and human oocytes (Antczak and Van Blerkom, 1997) , and the cellular domains thus established are maintained and reflected in the distribution of these proteins in the morula and blastocyst. Maternal factors are, therefore, obvious candidates in the search for developmental regulators.
With each subsequent cleavage, there is a loss of developmental potential in the blastomeres making up the preimplantation embryo (Edwards and Beard, 1997) . Activation of maternal determinants, and of embryo-specific genes, as well as external cues, may contribute to changes in the state of the cell. For example, compaction follows cell allocation at the 2-cell stage, but the process is also influenced by cell contacts and environmental parameters present in the 8-cell embryo (Edwards and Beard, 1997) . The processes of compaction, cavitation, and the formation of trophectoderm, inner cell mass (ICM), and subsequently, endodermal lineages are all critical events of preimplantation development. An understanding of how these processes are regulated must begin with identification of the factors involved.
for this stage of development. This includes two genes involved in cell-cell interactions and signaling mechanisms from the cell surface. Cadherins, cell surface adhesion molecules, are linked to the cytoskeleton through interactions with cytoplasmic proteins known as catenins and are critical for the compaction process (Kemler, 1993 , Gumbiner, 1995 . Targeted disruption of the E-cadherin gene demonstrated the requirement of E-cadherin for the formation of the trophectodermal cell layer (Larue et al., 1994; Riethmacher et al., 1995) . In addition, a gene trap mutation of α-E-catenin, a member of the catenin protein family, produces a similar early embryonic phenotype (Torres et al., 1997) . Both mutations result in lethality at the implantation stage.
The search for novel regulatory genes expressed specifically in the early embryo has been aided by differential screening of embryonic cDNA libraries (Rothstein et al., 1992; Temeles et al., 1994) . Many of these genes are also present as maternal mRNAs (Hwang et al., 1996) . One such gene, termed Spin, encodes the spindlin protein found associated with the meiotic spindle (Oh et al., 1997) . The maternal mRNA is translated in the 2-cell embryo, but spindlin is no longer detectable at the 8-cell stage. Spindlin is phosphorylated in a cell cycledependent manner, and in fact, is one of the previously described proteins found to be differentially phosphorylated during the first embryonic cleavages (Howlett, 1986; Oh et al., 1997) . Another early transcript associated with the 2-cell stage is derived from the gene for U2af binding protein-related sequence (U2afbp-rs), which is transiently expressed through the 8-cell stage (Latham et al., 1995) . U2afbp-rs is maternally imprinted, and the imprint is manifested in the preimplantation embryo from the time of gene activation.
Only a few transcription factors have been detected and studied in the cleavage-stage mouse embryo. Tbx3, a member of the T-box gene family, and Sox2, an Sry-related gene, are both expressed during the preimplantation period (Chapman et al., 1996; R. Lovell-Badge, personal communication) , while mTEAD-2, a member of the TEA DNA binding domain transcription factor family, is expressed both maternally and from the 2-cell stage (Kaneko and DePamphilis, 1997) . A family of nuclear transcription-requiring proteins (TRC) has been described, which are specifically expressed at the maternal to embryonic transition (Conover et al., 1991) . However, one of the best candidates for an embryonic regulatory factor is the transcription factor Oct-4. In this review, we will summarize what is known about the expression, regulation, and function of Oct-4, and will emphasize why this gene is both characteristically and functionally suited for playing a prominent role in early embryogenesis.
Oct-4 gene
Alternately designated as Oct-3, Oct-4, or POU5F1, this transcription factor is a member of the POU domain family of octamer-binding proteins (Ryan and Rosenfeld, 1997) . Oct-4 was first identified as a binding activity present in the extracts of undifferentiated embryonic stem (ES) and embryonal carcinoma (EC) cells (Schöler et al., 1989a; Lenardo et al., 1989; Okamoto et al., 1990) . Oct-4 is one of several factors which bind to the octamer site, an 8 bp element found in the promoter or enhancer regions of many ubiquitously expressed, as well as tissue-specific genes (Ruvkin and Finney, 1991) . The Oct-4 gene encodes a protein of 352 amino acids (Okamoto et al., 1990; Rosner et al., 1990; Schöler et al., 1990a) , which includes a conserved region of~150 amino acids, known as the POU domain. This region can be subdivided into the POU-specific and POU homeodomains which mediate sequence-specific DNA binding (Herr and Cleary, 1995) . Members of the POU gene family have been assigned to classes based on the amino acid homologies of their respective POU domains. Interestingly, all members of the class to which Oct-4 belongs are expressed during early embryonic development (Ryan and Rosenfeld, 1997) .
The Oct-4 gene is separated into five exons (Okazawa et al., 1991; Yeom et al., 1991) , which encode an mRNA transcript of~1.5 kb (Okamoto et al., 1990; Rosner et al., 1990; Schöler et al., 1990a) (Figure 2 ). The Oct-4 promoter region lacks a TATA box, and transcription is initiated at multiple sites (Okazawa et al., 1991) . The gene is located on mouse chromosome 17, and maps near the t-complex, within or immediately adjacent to the major histocompatibility complex (MHC) (Schöler et al., 1990b) . The proximity of the Oct-4 gene to the t-complex is intriguing as a number of t-complex alleles exhibit early embryonic lethal phenotypes associated with cells expressing Oct-4 (Schöler et al., 1990b) . However, no functional interactions between these genes and Oct-4 have yet been established.
The Oct-4 gene has been found only in mammalian species. The amino acid sequence of human Oct-4 (also called Oct3 or OTF) is 87% identical to that of the mouse, and the genomic organization, with regard to intron-exon boundaries is the same (Takeda et al., 1992; Abdel-Rahman et al., 1995) . The gene maps to human chromosome 6, in a region homologous to mouse chromosome 17. In contrast to the mouse, two transcripts are produced through alternative splicing, yielding proteins with different amino termini (Abdel-Rahman et al., 1995) . Although expression of these proteins has not yet been fully investigated, the existence of two factors with common DNA binding specificity, but different activation domains is likely to be functionally significant.
Expression of the Oct-4 gene
The presence of Oct-4 protein in ES and EC cells first suggested an association with the early stages of mouse embryogenesis. Subsequent analysis established that Oct-4 is expressed throughout the preimplantation period (Schöler et al., 1989a (Schöler et al., , 1990a Okamoto et al., 1990; Rosner et al., 1990 ) (see Figure 1 ). Oct-4 mRNA and protein are present in unfertilized oocytes, and the protein is localized to the pronuclei following fertilization (Schöler et al., 1989a; Rosner et al., 1990; Yeom et al., 1991; Palmieri et al., 1994) . As is typical of most maternal mRNAs, Oct-4 mRNA levels drop dramatically after fertilization (Yeom et al., 1991) , although Oct-4 protein is detectable in the nuclei of 2-cell embryos (Palmieri et al., 1994) . Zygotic Oct-4 expression is activated prior to the 8-cell stage, when levels of both mRNA and protein increase significantly in the nucleus (Yeom et al., 1991; Palmieri et al., 1994) . Expression of Oct-4 mRNA and protein is abundant and uniform in all cells of the embryo through the morula stage (32-64 cells). However, as the outer cells of the morula differentiate into trophectoderm, Oct-4 is down-regulated and becomes restricted to cells of the ICM in the blastocyst (Okamoto et al., 1990; Rosner et al., 1990; Schöler et al., 1990b) (Figure 3) .
At implantation, Oct-4 expression is concentrated in the primitive ectoderm (Rosner et al., 1990; Schöler et al., 1990b; Yeom et al., 1996) . In contrast to its down-regulation in trophectoderm, levels of Oct-4 protein transiently increase in 1024 cells of the primitive endoderm as they differentiate and migrate away from the ectoderm (Palmieri et al., 1994) . In the primitive ectoderm, Oct-4 expression persists through day 7.5 in the unsegmented presomitic mesoderm, decreasing anteriorly to posteriorly as the somites form (Rosner et al., 1990; Schöler et al., 1990b) . Thereafter, the expression of Oct-4 is strictly confined to the primordial germ cells (PGCs), precursors of the gametes. Not surprisingly, embryonic germ (EG) cells, derived from the in-vitro culture of PGC precursors (Labosky et al., 1994) , also express Oct-4 .
When ES or EC cells are induced to differentiate, Oct-4 mRNA expression is down-regulated (Lenardo et al., 1989; Schöler et al., 1989a) . The expression of Oct-4 is thus associated with undifferentiated cells, both in the preimplantation embryo, and in culture. Even more striking is the correlation between Oct-4 expression and differentiation potential; all totipotent and pluripotent cells of the embryo express Oct-4.
Oct-4 is both maternally and zygotically expressed in humans, and is present through the blastocyst stage (AbdelRahman et al., 1995) . In contrast to the mouse, reverse transcription-polymerase chain reaction (RT-PCR) revealed the presence of both alternatively spliced mRNAs in adult human somatic tissues (Takeda et al., 1992) . It remains to be determined whether human Oct-4 is also expressed in the germline.
Regulation of Oct-4 expression
Transgenic analysis of Oct-4 expression in the developing mouse embryo was carried out using a LacZ reporter gene linked to various regions of Oct-4 upstream sequences . An 18 kb genomic fragment was found to correctly reproduce the endogenous pattern of Oct-4 expression in both pre-and postimplantation embryos (Figure 4 ). Deletion analysis demonstrated that Oct-4 gene expression is dependent on at least three upstream cis-regulatory regions (Figure 2 ). The first of these is the promoter, located within the first 250 bp of the transcription initiation sites. A second region, the proximal enhancer, located 1.2 kb upstream, is known to mediate the repression of Oct-4 by retinoic acid (RA) (Okazawa et al., 1991) . Our analysis shows that this is a stage-specific enhancer required for Oct-4 expression in the primitive ectoderm . Finally, we have identified a third region, located 2 kb upstream, called the distal enhancer, which specifically drives expression of Oct-4 in the preimplantation embryo.
The Oct-4 proximal promoter contains a cluster of overlapping binding sites recognized by specific DNA binding proteins. These include a GC box which can bind members of the Sp1 transcription factor family, and three repeated half-sites of the consensus hormone response element (HRE) (Schoorlemmer et al., 1994; Sylvester and Schöler, 1994; M.Pesce and H.R.Schöler, unpublished) . This element resembles a canonical retinoic acid response element (RARE), and is recognized by a number of receptors belonging to the steroid thyroid hormone receptor family, including retinoic acid (RAR) and retinoid X receptors (RXR) (Okazawa et al., 1991; Pikarsky et al., 1994; Schoorlemmer et al., 1994; Sylvester and Schöler, 1994; Ben-Shushan et al., 1995) . Also overlapping this region is a putative binding site for ELP, a nuclear orphan receptor (Schoorlemmer et al., 1994; Sylvester and Schöler, 1994) .
Sp1 is thought to play a role in initiating transcription from promoters which lack a TATA box (Pugh and Tijan, 1991) . In undifferentiated cells and early mouse embryos, Sp1 can mediate the expression of an exogenously-introduced gene, while in differentiated cells, enhancer-stimulated promoter activity depends on a TATA box (Majumder and DePamphilis, 1994) . This may be a specific mechanism for restricting gene expression in undifferentiated cells (Nothias et al., 1995) . Transcription of Oct-4 in the preimplantation embryo, ES, and EC cells would rely on Sp1 binding, while Oct-4 downregulation in differentiating cells would be accelerated by the absence of a TATA box. Mutation of the GC box in the Oct-4 promoter abolishes expression in both ES and EC cells (Minucci et al., 1996) . However, in mice lacking Sp1, the expression of Oct-4 appears to be unaltered, suggesting that related family members may substitute for this factor (Marin et al., 1997; M.Pesce and H.R.Schöler, unpublished) . It is interesting to note that other genes vital to the preimplantation embryo, including E-cadherin and HCG β, also lack a TATA box (Otani et al., 1988; Ringwald et al., 1991) .
The proximal enhancer is a critical element for P19 EC cell-specific expression and RA-mediated down-regulation of Oct-4 (Okazawa et al., 1991) . In the developing embryo, the activity of this enhancer is limited to the primitive ectoderm . In undifferentiated cells of the preimplantation embryo, in ES cells and in F9 EC cells, the activity of the proximal enhancer is very low (Minucci et al., 1996; Yeom et al., 1996) . The enhancer contains a cis-acting element which responds to RA repression, although it does not encompass a recognizable RA receptor binding site (Okazawa et al., 1991) . This element can be subdivided into two sites (1A and 1B) (Figure 2 ). Both sites bind distinct factors in vitro (Okazawa et al., 1991) , but only site 1A is occupied in vivo in undifferentiated ES and EC cells (Minucci et al., 1996) . This site is GC-rich and related to the consensus Sp1 binding site in the promoter (Minucci et al., 1996) .
The second, distal enhancer is active in undifferentiated cells of the preimplantation embryo and, later in development, is also responsible for the lineage-specific expression of Oct-4 in primordial germ cells . ES and EG cells also require the distal enhancer for Oct-4 expression. Thus, the activity of this enhancer is restricted to totipotent and pluripotent cell types. Within the distal enhancer is a site called 2A, which is similar to, but in the opposite orientation of site 1A of the proximal enhancer (see Figure 2) . In vivo, genomic footprinting demonstrated that site 2A is also occupied in undifferentiated ES and EC cells (Minucci et al., 1996) . Several factors are known to bind within the distal enhancer region, and work to establish their identities is currently in progress.
The expression of Oct-4 in the developing embryo is, therefore, dependent on a combination of the promoter, proximal and distal enhancer activities. The enhancer activity is temporally regulated such that the distal enhancer is active in the ICM, while the proximal enhancer drives expression in the primitive ectoderm. The switch from distal to proximal enhancer activity occurs around implantation . Following down-regulation of Oct-4 during gastrulation, the distal enhancer once again becomes active in germ cell precursors. The restriction of distal enhancer activity to toti-and pluripotent cell types suggests that there is a set or unique combination of DNA-binding factors which may define the undifferentiated state.
Negative regulation of the Oct-4 gene
As development proceeds, Oct-4 expression in the embryo is progressively restricted. The link between cellular differ- entiation and Oct-4 down-regulation also exists in cultured ES and EC cells. However, the down-regulation of Oct-4 does not appear to be a prerequisite for differentiation, at least with respect to the trophectoderm or extraembryonic endoderm. Immediately prior to formation of the trophectodermal layer, the level of Oct-4 protein present in the outer cells of the compacted morula is as high as within the uncommitted inner cells (Palmieri et al., 1994) . While differentiation of the trophectodermal cells is accompanied by a decrease in Oct-4 protein levels, the protein level transiently increases in primitive 1026 endodermal cells as they differentiate into parietal endoderm and begin migrating (Palmieri et al., 1994) . Consistent with these observations, it has been found that differentiation of EC or ES cells by methods other than RA is not accompanied by a rapid decrease in Oct-4 expression (Okamoto et al., 1990; Schoorlemmer and Kruijer, 1991) .
Attempts to understand the relationship between Oct-4 down-regulation and differentiation have taken advantage of the ES and EC model systems. In cell hybrids between EC cells and fibroblasts, the expression of the Oct-4 gene is Oct-4-mediated repression of the Rex-1 gene (Ben-Shushan et al., 1998) . Recently, several general, as well as F9 cellspecific proteins, have been found to interact with Oct-4 in vitro (Tomilin et al., 1998) . The identity of these factors remains to be determined.
The Oct-4 protein contains two independent transactivation regions (Imagawa et al., 1991; Schöler et al., 1991; Vigano and Staudt, 1996; Brehm et al., 1997) . Both the amino (N domain) and carboxy termini (C domain) harbour significant numbers of proline residues, known to be associated with transcriptional activation domains (Mermod et al., 1989) . Both domains are active in undifferentiated and differentiated cells when fused to the DNA binding domain of Gal4. However, when linked to the Oct-4 POU domain, the C domain exhibits cell type-specificity (Brehm et al., 1997) . This is consistent with the observation that the POU domain serves to interact with secondary factors (Schöler, 1991; Brehm et al., 1997) . Most importantly, regulation by the POU domain is not observed with other transactivation domains, but appears to be specific for the Oct-4 C domain. The mechanism of regulation is not yet clear, but could involve a direct interaction between the POU and C domains (Brehm et al., 1997) . In support of this proposal, the C domain also displays cell-type specificity when linked to the POU domain of Oct-1, but not to that of Pit-1 (Brehm et al., 1997) . This may indicate that residues critical for the direct interaction of the domains are compatible between Oct-1 and Oct-4, but not with Pit-1.
Phosphorylation is known to influence the DNA binding and activity of several POU transcription factors (Ryan and Rosenfeld, 1997) . The Oct-4 protein is known to be phosphorylated in vivo (Rosfjord et al., 1995; Brehm et al., 1997) , but phosphorylation does not alter its ability to bind DNA (Rosfjord et al., 1995) . Nevertheless, there is a correlation between the phosphorylation status of the protein and the activity of the C domain (Brehm et al., 1997) . Post-translational modifications are most likely involved in Oct-4 regulation, probably by modulating the activity of specific domains of the transcription factor.
Function of Oct-4
In order to establish the function of Oct-4 in development, the gene has been inactivated in ES cells by homologous recombination (Mountford et al., 1994) . The phenotype resulting from this mutation should demonstrate how critical Oct-4 is for early development in the mouse.
In the meantime, an understanding of Oct-4 function is being gained through the examination of interactions and potential targets of the transcription factor. The Oct-4 protein has been reported to bind to regulatory regions of the Rex-1 gene (Ben-Shushan et al., 1998; Rosfjord and Rizzino, 1994) , the fgf-4 gene (Schoorlemmer and Kruijer, 1991; Yuan et al., 1995) , and the genes encoding human platelet-derived growth factor (PDGF) α receptor (Kraft et al., 1996) , the α and β subunits of human chorionic gonadotrophin (HCG) (Liu and Roberts, 1996; Liu et al., 1997) , a murine glucose transporter, as well as a number of genes not yet identified (Saijoh et al., 1996) . Both Rex-1, a zinc finger protein, and FGF-4 are expressed in ES and EC cells, and are rapidly decreased upon differentiation. As differentiation proceeds, Oct-4 binding on both genes is lost (Schoorlemmer and Kruijer, 1991; Rosfjord and Rizzino, 1994) . The Rex-1 and fgf-4 genes are also coexpressed with Oct-4 in the ICM (Niswander and Martin, 1992; Scherer et al., 1996) , strengthening the implication that these genes are targets for positive regulation by Oct-4. In fact, it has been established that regulation of the fgf-4 gene, which is known to be essential for ICM proliferation and perhaps, establishment (Feldman et al., 1995) , involves binding of a Sox2/Oct-4 complex to the 3Ј enhancer element (Yuan et al., 1995) . This enhancer is required for EC cell-specific expression of fgf-4 (Curatola and Basilico, 1990) . fgf-4 is thus a target gene of both Oct-4 and Sox2.
Oct-4 appears able to function in vivo either as a transcriptional activator, or a repressor (Ben-Shushan et al., 1998) . Binding of the Oct-4 protein is known to repress activity of the immunoglobulin heavy chain enhancer in F9 EC cells (Lenardo et al., 1989) . In co-transfection assays, murine Oct-4 has been found to silence transcription of both human HCG α and β, genes required for implantation and the maintenance of pregnancy (Liu and Roberts, 1996; Liu et al., 1997) . Both HCG subunits are first expressed as trophectoderm begins to differentiate, when the Oct-4 gene is normally downregulated (Hay and Lopata, 1988) . This could suggest that their expression is normally repressed by Oct-4, and coordinately activated as Oct-4 is down-regulated. In contrast, transcription from one of two alternative promoters on the PDGF α receptor (PDGFαR) gene is activated by Oct-4 binding (Kraft et al., 1996) . RA-induced differentiation of Tera2 EC cells results in Oct-4 down-regulation and promoter switching, such that alternative transcripts are generated.
Recent investigations in our laboratory have identified another potential target gene for Oct-4. Immunoprecipitation of DNA fragments bound in vivo by the Oct-4 protein has lead to the isolation of an Oct-4 recognition sequence located within the osteopontin (opn) gene (Botquin et al., 1998) . opn encodes a secreted phosphoprotein which binds, through an integrin-recognition sequence, to cells, as well as to components of the extracellular matrix (Denhardt and Guo, 1993) . A number of possible functions have been suggested for the opn protein, one of which is an involvement in cell migration. To assess the significance of Oct-4 binding to the opn gene, the expression patterns of the two genes were compared. Oct-4 and opn are co-expressed in ES and F9 EC cells, and both are down-regulated upon differentiation (Botquin et al., 1998) . In the embryo, opn mRNA becomes detectable at the morula stage, and is found in both the primitive ectoderm and primitive endoderm of 4.5 day blastocysts. Although Oct-4 expression is eventually restricted to the primitive ectoderm, a transient increase in Oct-4 protein levels occurs in the cells of the primitive endoderm as they differentiate and begin to migrate along the inner surface of the trophectoderm. The coexpression of Oct-4 and opn in premigratory endodermal cells is consistent with the proposal that Oct-4 is involved in the regulation of the opn gene, and that osteopontin is involved in cell migration.
The immunoprecipitated fragment, located within the first intron of the opn gene, includes an octamer recognition sequence, as well as adjacent sites recognized by Sox and engrailed-like factors (Botquin et al., 1998) . In correlation with Oct-4 activity, the 36 bp fragment can function as an enhancer in EC cells, but not in differentiated 3T3 cells. In contrast to the synergistic transactivation of fgf-4 by Oct-4 and Sox2, binding of Sox2 to the opn fragment represses the Oct-4-mediated increase in opn expression. As Oct-4 and Sox2 are co-expressed in the early embryo, their opposing actions on opn expression will need to be more precisely characterized.
Oct-4 and cell potency
Several facts suggest that Oct-4 may play a role in maintaining the pluripotency of a cell, and in the specification of the germ cell lineage. Oct-4 expression is confined to undifferentiated or differentiating cells of the embryo. It is unclear what defines totipotency and how this state is altered when a cell becomes committed. Expression of Oct-4 in the preimplantation embryo and primordial germ cells, pluripotent and totipotent cells, is dependent on the activity of the distal enhancer. In fact, the activity of this enhancer is strictly limited to these cells, and is not observed in differentiated cell types . This implies that a set or unique combination of DNA-binding factors must characterize the pluripotent cell.
Regulation by a distinct enhancer specifically required to drive expression in undifferentiated cells implies that the Oct-4 transcription factor is linked to the pluripotent state of these cells. Functional analysis confirms this link. One of two PDGFαR promoters is active and regulated by Oct-4 only in undifferentiated EC cells. In differentiated cells, promoter switching occurs. But, when Oct-4 is ectopically expressed, the promoter specific to undifferentiated cells is re-activated (Kraft et al., 1996) .
The down-regulation of Oct-4 in the primitive ectoderm coincides with the appearance of germ-cell precursors, located within the extraembryonic mesoderm at the proximal region of the embryo (Lawson and Hage, 1994) . Oct-4 expression in this small group of cells can be detected as early as embryonic day 8.5 , and is maintained throughout the germline (Pesce et al., 1998) . At this time, ectodermal expression of Oct-4 is dependent on the activity of the proximal enhancer, while germ cell expression relies on the distal enhancer . The enhancer switch could ensure that Oct-4 is present in the primitive ectoderm until specification of the germ cells, and is then turned off, while being maintained in the germ cell precursors, which must remain totipotent. This strengthens the speculation that Oct-4 itself is required for germ cell specification.
Conclusions
A number of precisely timed and regulated events occur during the preimplantation period of mouse development, which must be carefully programmed. Numerous observations lead to the conclusion that the Oct-4 transcription factor may be an important embryonic regulatory factor. Oct-4 is present as a maternal mRNA and subsequent expression of the gene occurs in every cell of the embryo until the first differentiation step. Thereafter, Oct-4 expression is linked to pluripotent cells from which the germline is derived.
Regulation of the Oct-4 gene is accomplished by two enhancers linked to a single promoter. One of the enhancers is active only in undifferentiated cell types, while the second drives expression in the embryo following implantation. Downregulation of Oct-4 appears to be tightly controlled at several levels, and there is an indication that the second enhancer is required.
The function of Oct-4 is presumed to involve the maintenance of an undifferentiated state, and also the determination or establishment of the germline. The putative targets so far identified for the Oct-4 transcription factor include a number of genes known to be critical for early development, such as fgf-4 and, in humans, HCG. Depending on the target, Oct-4 binding has been observed to mediate both activation and repression. Co-expression of Oct-4, fgf-4 and Sox2 suggests functional interactions which may be important for regulation of ICM versus trophectoderm formation. Likewise, the regulation of opn by Oct-4 reveals an interaction with the extracellular and cell-surface molecules which play a critical role in early embryonic differentiation. Altogether, it is likely that Oct-4 is responsible for various functions at several different embryonic stages. Regulation of the gene by separate cell-specific enhancers helps to co-ordinate these activities. Considering its expression profile, regulation and function, we conclude that Oct-4 must occupy a pre-eminent position within the regulatory hierarchy of genes controlling preimplantation development.
